Raptor Pharmaceutical Launches QUINSAIR™ in Europe

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Raptor Pharmaceutical Launches QUINSAIR™ in Europe

NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.   

Dave Happel, Raptor’s Chief Commercial Officer, said, “Raptor is excited to offer a new, first-in-class inhaled antibiotic treatment option for the many patients and families living with cystic fibrosis and battling chronic bacterial lung infections. We are beginning the European launch of QUINSAIR in Germany and Denmark, and continue to pursue approval of QUINSAIR for CF patients in the United States.” 

Happel added, “We are confident that QUINSAIR will be an important growth driver for Raptor. We expect QUINSAIR to increase our revenue base and enhance our long-term growth profile while leveraging our commercial and development expertise and our existing global infrastructure.”

About QUINSAIR TM (levofloxacin inhalation solution)

QUINSAIR is a proprietary inhaled formulation of levofloxacin, a fluoroquinolone antibiotic, which is approved in the European Union and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with CF. Administration of QUINSAIR with the high efficiency Zirela ® Nebulizer System (PARI Pharma GmbH) allows for the delivery of high concentrations of active drug directly to the site of infection in approximately five minutes. QUINSAIR is contraindicated in patients with hypersensitivity to levofloxacin, a history of tendon disorders related to fluoroquinolones, or epilepsy and also patients who may be pregnant or breast feeding. QUINSAIR's safety was evaluated in two double-blind, placebo-controlled studies and an active comparator study in which the most frequently reported adverse reactions were cough/productive cough, dysgeusia and fatigue/asthenia.

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-threatening genetic disease affecting approximately 75,000 people worldwide. CF is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Defective or missing CFTR protein causes poor flow of salt and water into or out of cells in several organs, including the lungs. This leads to the buildup of abnormally thick secretions that can cause chronic lung infections and progressive lung damage that in many patients eventually leads to death.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor is leading the global commercialization of two products for orphan diseases, including PROCYSBI®, for the management of nephropathic cystinosis in adults and children ages 2 years and older, and QUINSAIR TM , an inhaled fluoroquinolone antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). Raptor’s R&D pipeline includes RP103, known commercially as PROCYSBI, for Huntington's disease and mitochondrial disorders, including Leigh syndrome. Raptor holds several orphan drug designations, including orphan drug exclusivity for nephropathic cystinosis in the U.S. and EU. The pipeline also includes MP-376, known commercially as QUINSAIR, which has Qualified Infectious Disease Product (QIDP) designation for three distinct indications:  for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa , in patients with CF and in patients with non-cystic fibrosis bronchiectasis (BE), and in patients with nontuberculous mycobacteria (NTM). Raptor holds orphan drug designation in the U.S. for MP-376 for the treatment of CF, which, when added to the 5 years of exclusivity associated with QIDP designation, would confer 12 years of regulatory exclusivity upon FDA approval.

For additional information, please visit www.raptorpharma.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are indicated by words or phrases such as "believes," "expects," "anticipates," "estimates," "plans," "continuing," "ongoing," "projected" and similar words or phrases and relate to future events, including statements regarding: PROCYSBI as a treatment option for patients with nephropathic cystinosis, Huntington's Disease and mitochondrial disorders, including Leigh Syndrome, QUINSAIR as a treatment option, including timing of its launch, for patients with chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF) in Europe and Canada, Raptor's plans to further develop MP-376 in cystic fibrosis, bronchiectasis not associated with cystic fibrosis and potentially also nontuberculous mycobacteria and the timing and outcome of  those development programs and any discussions with regulatory authorities and Raptor's other development programs. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the company's actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Factors which may contribute to differences in actual results include, among others: Raptor's ability to market and sell QUINSAIR; continued and increased market acceptance and sales of PROCYSBI in the U.S. and other territories; Raptor's ability to expand the use of RP103 and MP-376 and to receive regulatory approval for other indications; Raptor's reliance on single active pharmaceutical ingredient suppliers for PROCYSBI and QUINSAIR and other third parties in connection with drug product development; compliance with healthcare regulations, ongoing regulatory requirements and potential penalties; any serious adverse side effects associated with PROCYSBI, QUINSAIR or any other future products; any product liability claims; third-party payor coverage, reimbursement and pricing for PROCYSBI, QUINSAIR and future products; enacted and future healthcare legislation; Raptor's ability to obtain and maintain orphan drug or other regulatory exclusivity for PROCYSBI, QUINSAIR or any other future products; the integration of European operations with U.S. operations; relationships with key scientific and medical collaborators; intellectual property protection and claims and continued license rights; and Raptor's ability to fund its operations and make required payments on its debt. Certain of these risks, uncertainties and other factors are described in greater detail in the company's filings from time to time with the Securities and Exchange Commission (SEC), which Raptor strongly urges you to read and consider, including: Raptor's annual report on Form 10-K for the twelve months ended December 31, 2015 filed with the SEC on February 26, 2016 and Raptor's other periodic reports filed with SEC, all of which are available free of charge on the SEC's web site at http://www.sec.gov . Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements except as may be required by law.

COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 robert.uhl@westwicke.com MEDIA CONTACT: Monica May Canale Communications (619) 849-5383 monica@canalecomm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 31

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 5

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 44

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 70

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading

Top 5 Most Recently Viewed Articles

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome

Updated Category News Views 124

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome FINTEPLA, known scientifically as fenfluramine, has demonstrated remarkable potential in treating seizures associated with Lennox-Gastaut syndrome (LGS) as confirmed by a significant open-label extension (OLE) study. This study emphasized the drug's beneficial effects, particularly in lowering seizure...

Continue Reading
Implications of U.S. Withdrawal from the Paris Agreement

Updated Category News Views 370

Significance of the U.S. Withdrawal from the Paris Agreement The decision by the U.S. to withdraw from the Paris Agreement is a critical moment not just for America, but for the entire globe. Analysts and climate diplomats suggest that this move will have far-reaching consequences, more profound than those witnessed during the initial exit in recent years. Accelerating...

Continue Reading
Ambarella's Oculii AI Technology Enhances Lotus Electric Vehicles

Updated Category News Views 236

Ambarella's Oculii AI Radar Transforms Lotus Vehicles In a major technological breakthrough, Ambarella has announced the worldwide rollout of its Oculii™ AI 4D imaging radar technology in Lotus's 2023 and 2024 electric vehicles. This advanced technology is integrated into the eye-catching Lotus Eletre electric hyper-SUV and the thrilling Lotus Emeya hyper-GT models....

Continue Reading
Luxury Brands Adapt to Broader Market with Affordable Options

Updated Category News Views 355

Luxury Brands Embrace Affordability for Wider Appeal In recent times, luxury brands have found themselves in a challenging position. With diminishing demand for high-priced items like $3,000 handbags and $4,000 cashmere jackets, many luxury labels are shifting their focus. They are creating a wider array of products targeting the middle-class customer, including...

Continue Reading
Elife Group's Game-Changing Platform for Global Transport Solutions

Updated Category News Views 328

Elife Group Launches Revolutionary Multi-Modal Travel Platform Elife Group has introduced an innovative multi-modal platform that redefines ground transportation. By seamlessly integrating rail and ride-hailing services into a single platform, they have created a comprehensive solution for travelers seeking convenient and efficient options. This strategic move positions...

Continue Reading